Key Moments
Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams
Andrew HubermanKey Moments
Dr. Nolan Williams discusses brain stimulation, psychedelics, and neuroplasticity for mental health.
Key Insights
Depression is the most disabling condition worldwide, affecting both mental and physical health, with limited traditional treatments.
Transcranial Magnetic Stimulation (TMS), particularly targeting the left dorsolateral prefrontal cortex, can restore brain network function in depression by re-establishing top-down control.
Psychedelics like ketamine, psilocybin, MDMA, and ibogaine show promise for treating severe depression, PTSD, and addiction, often by inducing a 'plastic state' for memory reconsolidation.
The antidepressant effects of psychedelics may not solely depend on the psychological 'trip' but also involve specific neuropharmacological or circuit-level changes.
SSRIs are effective for some forms of depression and anxiety, but the long-held 'chemical imbalance' theory is challenged by circuit-based treatments like TMS.
Sleep deprivation combined with timed light exposure and phase shifting (triple therapy) can provide temporary relief from depression by resetting circadian rhythms.
Cannabis's effects on mental health are complex, with CBD showing anti-psychotic and anti-epileptic properties, while high THC potency can exacerbate psychosis, especially in developing brains.
Responsible, clinically supervised use of psychedelics, as opposed to recreational use, is crucial due to their powerful effects on consciousness and the potential for long-lasting therapeutic change.
The 'STN' (Stanford Neuromodulation Therapy) is a rapid and highly effective TMS protocol that delivers an intensive, individualized dose of stimulation over five days, showing high remission rates for severe depression.
THE GLOBAL BURDEN AND MISUNDERSTOOD NATURE OF DEPRESSION
Dr. Nolan Williams emphasizes that depression is the most disabling condition globally, often underappreciated in its severity—moderate depression is as debilitating as a heart attack, severe depression akin to untreated cancer. Intriguingly, depression is now recognized as the fourth major risk factor for coronary artery disease by the American Heart Association. Despite its profound impact, psychiatry faces a paradox: as the acuity of a patient's depression increases (e.g., suicidal ideation), the number of available treatments typically decreases, and there are often no objective diagnostic tests. This highlights a critical need for new, brain-based interventions.
THE BRAIN-HEART CONNECTION IN MOOD REGULATION
Williams details a direct, physical connection between the brain's mood-regulatory regions and the heart. Transcranial Magnetic Stimulation (TMS) applied to the left dorsolateral prefrontal cortex (dlPFC) can induce a synchronized deceleration of heart rate, suggesting this area acts as a 'governor' for the heart. While this immediate heart rate change is more of a marker that the correct neural network is being targeted rather than a direct therapeutic mechanism, it underpins the concept of a brain-heart axis. This connection is also evident in vagus nerve stimulation, which can alleviate depression by influencing these same brain regions.
HEMISPHERIC BALANCE AND THE DLPRFC AS A 'HINGE'
The left and right dlPFC exhibit a fascinating hemispheric lateralization in mood regulation: exciting the left dlPFC or inhibiting the right can reduce depressive symptoms, while stimulating the right can have anti-manic effects. This suggests a delicate balance. Williams posits that the dlPFC may act as the 'hinge' of the autonomic nervous system, regulating the seesaw between states of alertness and calmness. In depression, this hinge loses control, leading to an inability to shift out of negative or overwhelmed states. The dlPFC's role in executive function and 'rule-switching,' as seen in tasks like the Stroop test, suggests it provides flexibility to our internal belief systems, which can become rigidly negative in depression.
SSRIs: MECHANISM AND THE 'CHEMICAL IMBALANCE' DEBATE
Selective Serotonin Reuptake Inhibitors (SSRIs) clearly work for many individuals with depression, OCD, and anxiety disorders, as evidenced by meta-analyses. However, Williams challenges the popularized 'chemical imbalance' theory, aligning with recent scientific consensus. The delayed onset of SSRI effects (weeks, not immediate) suggests their therapeutic action isn't merely about increasing serotonin levels, but likely involves downstream effects like neuroplasticity (e.g., upregulation of brain-derived neurotrophic factor). This reframes depression not as a 'something missing' issue, but a 'circuit problem' that is potentially fixable, offering patients a sense of agency and hope for recovery.
KETAMINE: DISSOCIATION, OPIOID MECHANISMS, AND NEUROPLASTICITY
Ketamine, a dissociative anesthetic, uniquely offers rapid antidepressant effects, typically lasting about a week and a half. The level of dissociation experienced during ketamine treatment appears necessary but not solely sufficient for its therapeutic benefit. Williams's research demonstrated that blocking opioid receptors with naltrexone dramatically reduced ketamine's antidepressant effects without impacting dissociation. This suggests that ketamine's opioid properties are crucial to its antidepressant action, challenging the idea that only the psychological 'trip' matters. Ketamine, like TMS, also promotes dendritic spine enlargement, indicating its role in fostering neuroplasticity.
PSILOCYBIN AND MDMA: RECONSOLIDATING TRAUMA AND DEPRESSION
Psilocybin and MDMA are showing significant promise for long-lasting relief from depression and PTSD, respectively, in clinical trials. MDMA-assisted therapy for PTSD has shown about two-thirds of patients achieving clinically significant improvement, lasting for years in some cases. Psilocybin for depression has shown a third to two-thirds efficacy, depending on the study type. These substances induce a 'plastic state' that allows individuals to re-experience and reconsolidate traumatic or depressive memories with a new perspective, fostering empathy and self-forgiveness. This 'letting go' of rigid, negative thought patterns—akin to exposure and response prevention therapy—is a key therapeutic component.
IBOGAINE: THE 'LIFE REVIEW' PSYCHEDELIC WITH UNIQUE RISKS
Ibogaine, derived from the iboga tree root bark, is an atypical psychedelic known for inducing profound 'life review' experiences, often described as '10 years of psychotherapy in a night.' Unlike psilocybin or LSD, it primarily causes vivid closed-eye visions of past memories, allowing individuals to re-experience events from a detached, empathetic third-person perspective. Williams's team is conducting the first comprehensive neurobiological study of ibogaine in former Navy Seals for PTSD and TBI. Despite its therapeutic potential, ibogaine carries significant cardiac risks, necessitating strict medical supervision and screening. It is not a recreational substance, often described as 'hard work,' but holds significant promise for profound, lasting change, particularly in addressing 'moral injury'.
AYAHUASCA: A SYMBIOTIC PLANT MEDICINE AND BEHAVIORAL CHANGE
Ayahuasca, a plant-derived psychedelic from the Amazon, requires the combination of two plants: one containing DMT and another containing a reversible monoamine oxidase inhibitor (MAOI). This ingenious combination allows orally ingested DMT to bypass digestive breakdown and cross the blood-brain barrier. Studies have explored its antidepressant effects and surprisingly, its impact on recidivism rates in Brazilian prisoners. In a study, prisoners who received ayahuasca showed a statistically significant lower return-to-prison rate than controls. This points to ayahuasca's potential to alter behavioral patterns and deeply ingrained drivers of criminal activity through its profound effects on consciousness and self-reflection.
CANNABIS: CBD VS. THC AND DEVELOPMENTAL VULNERABILITY
Williams clarifies the complex nature of cannabis, emphasizing the distinct effects of its main cannabinoids: THC and CBD. High-potency THC is considered pro-psychotic and pro-epileptic, with clear cases of acute psychosis resolving upon THC clearance. Conversely, CBD demonstrates anti-psychotic and anti-epileptic properties, even used to treat severe pediatric seizure disorders. The concern with cannabis, particularly high-THC strains, lies in its use during prefrontal maturation (up to age 25), with evidence suggesting early, potent cannabis use can exacerbate psychosis later in life. This highlights the importance of understanding cannabinoid ratios and developmental timing.
REDRAWING THE DRUG RISK LANDSCAPE: ALCOHOL VS. PSYCHEDELICS
Citing David Nutt's research, Williams underscores the disproportionate societal perception of drug risks. Alcohol, when considering both personal and societal harm (e.g., drunk driving, violence, health issues), consistently ranks as the most dangerous drug, surpassing heroin and cocaine. Cannabis places in the middle, while psilocybin and caffeine are at the lowest end of the risk spectrum. This stark contrast between scientific evidence and cultural acceptance, particularly regarding alcohol, suggests a substantial 'tipping point' is yet to be reached, similar to the historical shift in public and medical perception of tobacco.
SLEEP DEPRIVATION AND TRIPLE THERAPY FOR DEPRESSION
Paradoxically, total sleep deprivation for one night can acutely improve depressive symptoms, though the effect is lost upon subsequent sleep. This phenomenon led to the development of 'triple therapy': a precise combination of one night of sleep deprivation, a calculated phase shift in sleep schedule, and timed bright light exposure. The theory is that this resets the dysregulated circadian system often implicated in depression. This therapy has shown durable antidepressant effects in trials but requires professional supervision due to its complexity and the potential for increased anxiety in non-depressed or highly anxious individuals.
THE SAINT STUDY: ACCELERATED NEUROMODULATION THERAPY (STN)
Dr. Williams's lab developed 'SAINT' (Stanford Accelerated Intelligent Neuromodulation Therapy), now called 'STN' (Stanford Neuromodulation Therapy), a revolutionary TMS protocol. It reconfigures traditional TMS by delivering the full six-week course of stimulation over just five days, utilizing 'space learning theory' to optimize brain plasticity. By applying 90 minutes of stimulation per day, spread hourly over ten hours, STN delivers seven and a half months' worth of stimulation in five days. Crucially, functional connectivity MRI scans are used to precisely target the specific subgenual dlPFC circuit for each individual. This intensive, individualized approach has shown remarkable results, with 60-90% of severely depressed patients achieving full remission within one to five days, often without the side effects associated with SSRIs, and with durable effects for some. The STN treatment has received FDA clearance, and clinical trials are ongoing to make this widely available, aiming to provide a powerful, circuit-based solution for treatment-resistant depression.
Mentioned in This Episode
●Supplements
●Products
●Software & Apps
●Companies
●Organizations
●Books
●Drugs & Medications
●Concepts
●People Referenced
Common Questions
Depression manifests in various ways, from loss of interest and under-activity to anxiety and over-activity. It is the most disabling condition worldwide, serving as a risk factor for other illnesses like coronary artery disease and exacerbating existing medical and psychiatric conditions.
Topics
Mentioned in this video
Host of the Huberman Lab podcast and professor of neurobiology and ophthalmology at Stanford School of Medicine.
Guest on the podcast, medical doctor and professor of Psychiatry and Behavioral Sciences at Stanford University School of Medicine. His lab focuses on depression treatments combining TMS with psychedelics.
A collaborator with Dr. Nolan Williams, known for his work on hypnotizability and its connection to parts of the left dorsolateral prefrontal cortex.
A researcher at Johns Hopkins running clinical trials on psilocybin, who discussed the importance of 'letting go' during psychedelic journeys.
A researcher at Harvard who demonstrated that strokes causing depression are functionally connected to the left dorsolateral prefrontal cortex, and mania to the right.
A former colleague of Andrew Huberman at Stanford, now at the University of Pennsylvania, who discussed Deep Brain Stimulation on another podcast.
Dr. Williams's mentor, who had the insight to combine the understanding of underactivity in the prefrontal cortex in depression with the ability of TMS to increase activity.
A prominent researcher from the UK who, along with David Nutt, pioneered neuroimaging work on psychedelics.
An Argentinian psychiatrist who wrote many books describing the ibogaine experience of re-evaluating earlier life memories from empathy and detachment.
A professor at Stanford interested in sleep, who explored the concept of sleep deprivation potentially improving depression symptoms but acutely.
A senior neuroscientist who approached Dr. Williams about funding a study on Navy SEALs using ibogaine and 5-MeO-DMT.
A prominent researcher from the UK who, along with Robin Carhart-Harris, pioneered neuroimaging work on psychedelics and published an article on relative drug risks.
An American who reportedly brought ibogaine from Africa to treat substance abuse, becoming sober after a profound experience.
The common name for the animal that produces 5-MeO-DMT, often referred to as 'the Toad'.
A sleep expert whose work has highlighted the importance of quality sleep for mental health, physical health, and high performance.
A drug increasingly used to treat depression, with effects that may not arise from its dissociative properties, and a focus of research in Dr. Williams's lab.
An experimental drug mentioned as a cutting-edge treatment under clinical trial for depression and other mood disorders, used in combination with TMS by Dr. Williams's lab.
An experimental drug with anti-trauma properties that preliminary data show promise for the treatment of depression and other mood disorders, used in combination with TMS by Dr. Williams's lab.
A class of antidepressants that block serotonin reuptake, used to treat depression, OCD, and anxiety disorders, but whose mechanism is not directly linked to a serotonin deficit.
An experimental drug with hallucinogenic properties that preliminary data show promise for the treatment of depression and other mood disorders, used in combination with TMS by Dr. Williams's lab.
A flavor of DMT, often called 'the Toad' from the Sonoran River toad, used sacramentally and lasting longer than traditional DMT. Used by Navy SEALs after ibogaine in a two-part treatment.
A psychedelic sacrament used in South American countries, combining two plants to allow DMT to cross the blood-brain barrier orally. Explored as an antidepressant and for reducing recidivism rates in Brazilian prisons.
A mu and kappa opiate receptor antagonist used in a study to block the antidepressant effect of ketamine, revealing the opioid system's role in ketamine's efficacy.
A beta-blocker that was once thought to cause depression, but this notion has been debunked.
High cholesterol, listed as a major risk factor for coronary artery disease alongside depression.
A brain region involved in mood regulation, whose connectivity with the default mode network changes both with effective TMS and psilocybin treatment for depression.
A psychological principle stating that learning is optimized when information is revisited at spaced intervals (e.g., every hour to an hour and a half), applied to the SAINt TMS protocol.
A neuromodulation technique mentioned by Casey Halpern on another podcast, similar to TMS and tDCS in perturbing brain regions.
Cognitive Behavioral Therapy specifically designed to help with insomnia, often involving strict rules about bedroom usage.
A brain stimulation technique that activates or quiets specific brain circuits to treat depression and mood disorders, often combined with other treatments in Dr. Williams's lab.
A psychological task used to study cognitive control, where individuals name the color of words, especially when the word itself names a different color.
A protein that gets upregulated with chronic oral antidepressant use, suggesting brain plasticity effects as part of the antidepressant mechanism.
A network of brain regions involved in self-referential thought, whose connectivity with the subgenual anterior cingulate is altered in depression and restored by TMS and psilocybin.
An extreme form of depression or other illnesses where people become motorically stuck and have very limited control, sometimes also seen as an outcome of conditions affecting the cingulate.
A cranial nerve that connects to the heart, which can be stimulated to alleviate depression, suggesting a direct brain-heart connection.
The principle behind Transcranial Magnetic Stimulation (TMS), using a magnetic pulse to induce an electrical current in brain tissue.
A hormone whose compensatory increase after a dopamine surge from MDMA may contribute to post-drug fatigue and mood/libido numbing.
A scientific journal where a paper was published in 2005 demonstrating that hippocampal rhythms through a TMS coil could excite the brain for an hour.
A rapid 5-day TMS approach developed by Dr. Williams's lab that can induce remission in depressed individuals by reorganizing stimulation in time and targeting specific brain circuits.
A gold-standard treatment for OCD that involves exposing individuals to anxiety triggers and preventing compulsive responses, fostering 'letting go'.
A project mapping connections between neurons, used as a reference to identify regions functionally connected to areas damaged by strokes that cause mood disorders.
A specific institute within the NIH that funded Dr. Halpern's research on MDMA.
The institution where Dr. Huberman is a professor of neurobiology and ophthalmology and Dr. Williams is a professor of Psychiatry and Behavioral Sciences.
A group of Special Operations individuals who have used ibogaine and 5-MeO-DMT in Mexico to treat PTSD and TBI, and are subjects in an ongoing study by Dr. Williams's lab.
An organization conducting clinical trials for MDMA, with a standard dose of 150-175mg.
A religious and sacramental group in Gabon that traditionally uses iboga root bark.
Dr. Nolan Williams's laboratory at Stanford, which is recruiting subjects for clinical trials for depression and other mood disorders.
An organization that added depression as the fourth major risk factor for coronary artery disease.
A university with a chemistry lab that published work on modifying psychedelics to remove hallucinogenic properties while retaining mood-altering effects.
An organization where two groups studied mood neuroanatomy and TMS, laying the groundwork for depression treatment.
An institute within NIH where research on TMS for motor cortex stimulation contributed to developing TMS for depression.
Institution where Dr. Wagner, a neuropsychologist for early MDMA trials, was a mentor to Dr. Williams.
An institute where psychiatric patients can go through clinical trials to receive TMS treatment for depression.
One of the depression scales used, where a score from 0 to 10 is considered within the normal range.
A subscription channel from the Huberman Lab podcast featuring AMAs, transcripts, and videos of new mental and physical health tools, with proceeds supporting scientific research.
A neuromodulation technique mentioned alongside TMS and deep brain stimulation as capable of focally and directly perturbing brain regions.
An experimental drug mentioned as one of the cutting-edge treatments under investigation.
A partner of the Huberman Lab podcast, offering supplements for enhancing sleep, focus, cognitive ability, energy, and hormone optimization.
An experimental drug mentioned as one of the cutting-edge treatments under investigation.
A non-psychoactive cannabinoid in cannabis, which has anti-epileptic and anti-psychotic properties, and is considered safe.
The psychoactive component of cannabis, which can be bred for high potency and is considered pro-psychotic and pro-epileptic, especially in adolescents.
A personalized nutrition platform that analyzes blood and DNA data to provide recommendations for reaching health goals through nutritional, behavioral, and supplement-based tools.
A company producing high-quality eyeglasses and sunglasses designed for performance, developed by All-American swimmers from Stanford.
A company founded by some of Dr. Williams's students, which has received FDA clearance for the SAINt treatment and is working to make it nationally available.
A smart mattress cover with cooling, heating, and sleep tracking capabilities designed to optimize body temperature for deep sleep and enhance overall health and performance.
A vitamin, mineral, and probiotic drink that supports foundational nutritional needs, gut health, and overall well-being. It also includes adaptogens.
A company conducting clinical trials for CBD-based treatments for seizure disorders like Dravet syndrome and Lennox-Gastaut syndrome.
High blood sugar, listed as a major risk factor for coronary artery disease alongside depression.
A severe seizure disorder in children that has been treated with CBD by GW Pharmaceuticals.
High blood pressure, listed as a major risk factor for coronary artery disease alongside depression.
A medical condition for which depression is now considered a major risk factor, alongside hypertension, hyperlipidemia, and diabetes.
A severe seizure disorder in children that has been treated with CBD by GW Pharmaceuticals.
More from Andrew Huberman
View all 342 summaries
40 minBenefits of Sauna & Deliberate Heat Exposure | Huberman Lab Essentials
148 minAvoiding, Treating & Curing Cancer With the Immune System | Dr. Alex Marson
31 minEssentials: The Biology of Taste Perception & Sugar Craving | Dr. Charles Zuker
189 minUnlearn Negative Thoughts & Behaviors Patterns | Dr. Alok Kanojia (Healthy Gamer)
Found this useful? Build your knowledge library
Get AI-powered summaries of any YouTube video, podcast, or article in seconds. Save them to your personal pods and access them anytime.
Try Summify free